Abstract | AIM: METHODS: Thirty-six obese women with PCOS (mean ± SD, aged 31.2 ± 7.8 years, with BMI 38.7 ± 0.1 kg/m(2)), pretreated with metformin (1000 mg BID) were switched to liraglutide 1.2 mg QD sc for 12 weeks. Adiposity parameters and eating behavior as assessed by Three-Factor Eating Questionnaire (TFEQ-R18) were examined at baseline and after 12 weeks. RESULTS: Subjects treated with liraglutide lost on average 3.8 ± 0.1 kg (p < 0.001). Significant reductions of waist circumference and visceral adipose tissue (VAT) mass, volume and area were demonstrated from liraglutide induction to the end of the study. TFEQ-R18 scores were significantly different pre- and post- liraglutide intervention. After treatment with liraglutide the uncontrolled eating (UE) score decreased from 36.8 ± 24.5 to 19.6 ± 18.4 (p < 0.001) and emotional eating (EE) score decreased from 49.9 ± 33.3 to 28.5 ± 26.9 (p < 0.001). Scores for cognitive restraint (CR) were not changed. CONCLUSIONS: Short-term liraglutide treatment was associated with weight loss and significantly improved eating behavior in obese women with PCOS.
|
Authors | Mojca Jensterle, Tomaz Kocjan, Nika Aleksandra Kravos, Marija Pfeifer, Andrej Janez |
Journal | Endocrine research
(Endocr Res)
Vol. 40
Issue 3
Pg. 133-8
( 2015)
ISSN: 1532-4206 [Electronic] England |
PMID | 25330463
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Hypoglycemic Agents
- Insulin
- Liraglutide
|
Topics |
- Adult
- Blood Glucose
- Body Mass Index
- Body Weight
(drug effects)
- Feeding Behavior
(drug effects)
- Female
- Humans
- Hypoglycemic Agents
(pharmacology, therapeutic use)
- Insulin
(blood)
- Intra-Abdominal Fat
(pathology)
- Liraglutide
(pharmacology, therapeutic use)
- Obesity
(complications, drug therapy, pathology)
- Polycystic Ovary Syndrome
(complications, drug therapy, pathology)
- Waist Circumference
- Young Adult
|